about
Gene doping: gene delivery for olympic victoryTumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenovirusesVectors for the treatment of autoimmune disease.Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal musclePhotodynamic therapy platform based on localized delivery of photosensitizer by vaterite submicron particles.The peritoneal tumour microenvironment of high-grade serous ovarian cancer.Novel delivery methods to achieve immunomodulation.Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth.Latent cytokines for targeted therapy of inflammatory disorders.Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.Identification of ZDHHC14 as a novel human tumour suppressor gene.Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.Generation of an efficiently secreted, cell penetrating NF-κB inhibitor.A novel hybrid promoter responsive to pathophysiological and pharmacological regulationTumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation.Endogenous GATA factors bind the core sequence of the tetO and influence gene regulation with the tetracycline system.Potentiation of TNF-alpha toxicity by conjugation with ricin A-chain.Gene therapy for rheumatoid arthritis. Theoretical considerations.Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritisA comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints.The Tetracycline Responsive System.Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging.Multi-layer microcapsules: fresh insights and new applications.Development of new molecules, vectors and cells for therapy of arthritis.Ceria Nanoparticles-Decorated Microcapsules as a Smart Drug Delivery/Protective System: Protection of Encapsulated P. pyralis Luciferase.In-situ NIR-laser mediated bioactive substance delivery to single cell for EGFP expression based on biocompatible microchamber-arrays.Inducible diabetes and transgene expression in a single mouse: a tool to elucidate autoimmune mechanismsGene doping: Olympic genes for Olympic dreamsLessons in microcapsule assembly from imaging delivery of a bioluminescent enzymeInitial Considerations Before Designing a Promoter ConstructDemonstrating Interactions of Transcription Factors with DNA by Electrophoretic Mobility Shift AssayPCR Assembly of Synthetic PromotersMagnetically targetable microcapsules display subtle changes in permeability and drug release in response to a biologically compatible low frequency alternating magnetic field
P50
Q26995443-6A53A76E-0FAC-4CE6-A16E-680B44BC9CDCQ33425253-E88369A7-9DA5-4EFA-9893-02038435E2B0Q35122178-1863D1CF-BAB3-48F4-9CF1-8997AE413C06Q35646675-E5871CF2-B9EE-44B5-AD2A-FBCF9A71FCC1Q36056240-CC8A5E9D-69E8-4E18-908A-B3D71B34C24DQ36719074-5FA729A0-712C-4CEC-B7DA-90D35EE327EBQ36870418-764AFDDD-2B17-438D-B662-B6D4222EA8E3Q37353781-75DDC990-5FC1-4527-8860-C0F5F43478B3Q38167818-8CD3F525-DFA8-4F42-87B9-A657280A2B85Q38477522-8CD79EDE-4552-4036-A2F8-53E459ABCB14Q39035797-584B488F-184C-4A8B-881A-4780554080F6Q39090650-20A8C3CA-A576-4FA9-A7CD-F37D822DE4B0Q39090683-E6A5D962-6155-4ACE-8C4A-E240E5703F75Q39450777-4E2B38EF-9062-4141-9C67-6E36A22C68BCQ40499389-41D50F2A-20F9-4AEE-A0CF-978EFAB30F57Q40539274-D02D83A3-F370-4344-826D-BB70BD567E76Q40970397-F7D9B8AE-7924-45A8-B9BE-9B3C5BC39C50Q41702950-5930A2A9-C57D-48EE-AAE7-9388D0E4572DQ42084870-596375C0-02A7-47ED-B940-39E3E8E943B1Q42222701-B6016879-850C-4F41-8A11-0FB0F2F83605Q42286946-2D00DB22-033A-409E-8290-2B71E4504D6DQ45870688-FD6F3FE1-8E97-474B-BA74-89E1D8D704B6Q50632322-2B312083-0705-41C7-81AF-E4790B9B8731Q51029597-75EBF8C9-1F9A-4F8A-AE41-F247E22B40A1Q51787026-85B905F6-6558-43DA-9691-4ECF5F95DAA3Q52596860-309EA507-5445-456F-8F05-6A3B4CB24633Q53839986-2F9E2B1F-8695-4A67-8626-9708FCA39A24Q78737909-92AE9CCB-D7F1-47D0-88C8-068F594F1C14Q83011609-30F04D2F-503E-487D-A5C8-36A58835BBCBQ86092441-F8A13610-0E77-4B6D-BD86-55850E94800CQ88760385-E2ABC1C9-6EEE-458D-A898-5362B67CE05AQ88760391-9005DB87-1639-4C2B-A2C8-ED37C7A7A707Q88760407-7EB12F62-933F-4EFC-8F74-5FA56606A115Q93040236-A35167D9-9861-4D7E-B4B6-0E364C4783A6
P50
description
researcher
@en
name
David J. Gould
@en
Gould DJ
@nl
type
label
David J. Gould
@en
Gould DJ
@nl
altLabel
Gould DJ
@en
prefLabel
David J. Gould
@en
Gould DJ
@nl
P106
P31
P496
0000-0003-4265-3635